The 13 references in paper V. Smirnov V., E. Egorenkov A., L. Krasnykh M., G. Vasilenko F., G. Ramenskaya V., В. Смирнов В., Е. Егоренков А., Л. Красных М., Г. Василенко Ф., Г. Раменская В. (2018) “Определение активности ферментов метаболизма лекарственных средств - перспектива использования в клинической практике // Determination of the activity of drug-metabolizing enzymes - the prospects for their use in clinical practice” / spz:neicon:vedomostincesmp:y:2016:i:4:p:28-32

1
Kukes VG. The metabolism of medicines: clinical and pharmacological aspects. Moscow: Reafarm; 2004 (in Russian).
(check this in PDF content)
2
Kukes VG, Bochkov NP, eds. Clinical pharmacogenetics. Moscow: GEOTAR; 2007 (in Russian).
(check this in PDF content)
3
Hedgecoe AM. Terminology and the construction of scientific disciplines: the case of pharmacogenomics. Science, technology and human values 2003; 28: 513–37; Hedgecoe A. The politics of personalized medicine — pharmacogenetics in the clinic. Cambridge University Press; 2004.
(check this in PDF content)
4
Hocum BT, White JR, Heck JW, Thirumaran RK, Moyer N, Newman R, Ashcraft K. Cytochrome P450 gene and drug interaction analysis in patients referred for pharmacogenetic testing. Am J Health Syst Pharm. 2016; 73(2): 61–7.
(check this in PDF content)
5
Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA. Applications of CYP450 testing in the clinical setting. Mol Diagn Ther. 2013; 17(3): 165–84.
(check this in PDF content)
6
Khojasteh SC, Prabhu S, Kenny JR, Halladay JS, Lu AY. Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet. 2011; 36(1): 1–16.
(check this in PDF content)
7
Emoto C, Murayama N, Rostami-Hodjegan A, Yamazaki H. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution. Curr Drug Metab. 2010; 11(8): 678–85.
(check this in PDF content)
8
Spaggiari D, Geiser L, Daali Y, Rudaz S. A cocktail approach for assessing the in vitro activity of human cytochrome P450s: an overview of current methodologies. J Pharm Biomed Anal. 2014; 101: 221–37.
(check this in PDF content)
9
Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther. 1995; 58(6): 641–9.
(check this in PDF content)
10
Stearns RA, Chakravarty PK, Chen R, Chiu SH. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug metabolism and disposition: the biological fate of chemicals. Drug Metab Dispos. 1995; 23(2): 207–15.
(check this in PDF content)
11
Yun CH, Lee HS, Lee H, Rho JK, Jeong HG, Guengerich FP. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174. Drug Metab Dispos. 1995; 23(2): 207–15.
(check this in PDF content)
12
Choi JS, Choi I, Choi DH. Effects of nifedipine on the pharmacokinetics of repaglinide in rats: possible role of CYP3A4 and P-glycoprotein inhibition by nifedipine. Pharmacol Rep. 2013; 65(5): 1422–30.
(check this in PDF content)
13
Zong H, Zhuge B, Lu X, Huo X, Fang H, Song J, Sun J. Characterization of a novel cytochrome P450 from Amycolatopsis sp. CGMCC1149 for hydroxylation of lovastatin. Biotechnol Appl Biochem. 2015; 62(1): 9–16. AUTHORS
(check this in PDF content)